胃轻瘫的流行病学、病因与治疗:基于美国大型全国理赔数据库的真实世界证据
该研究利用美国Optum理赔数据库回顾性分析成人胃轻瘫的患病率、人口学特征与病因。标准化患病率为267.7/10万,明确胃轻瘫为21.5/10万;糖尿病病因最常见(57.4%),合并症负担重。
要点
- 美国成人胃轻瘫标准化患病率为267.7/10万,明确胃轻瘫为21.5/10万。
- 糖尿病是最常见病因(57.4%),其中2型占51.7%,1型占5.7%。
- 患者Charlson合并症指数平均4.2,慢性肺病、糖尿病慢性并发症常见。
核心结论
- 美国成人胃轻瘫总体标准化患病率为267.7/10万,明确胃轻瘫为21.5/10万。
- 糖尿病是最常见病因,占57.4%,术后、药物性和特发性病因次之。
研究设计与样本
- 回顾性横断面分析,使用美国Optum Clinformatics Data Mart理赔数据库的成人纵向参保与账单数据。
- 患病率按2018年美国人口普查进行年龄、性别和地理区域标准化。
主要发现
- 总体标准化患病率为267.7(95%CI 264.8-270.7)/10万美国成人。
- 明确胃轻瘫(胃排空闪烁显像检查后3个月内诊断且症状持续超过3个月)患病率为21.5(95%CI 20.6-22.4)/10万。
- 患者Charlson合并症指数平均4.2;最常见合并症为慢性肺病(46.4%)、伴慢性并发症的糖尿病(37.3%)和外周血管病(30.4%)。
- 病因分布:糖尿病57.4%(1型5.7%,2型51.7%)、术后15.0%、药物性11.8%、特发性11.3%。
临床怎么用
- 临床应关注胃轻瘫患者的高合并症负担,尤其是慢性肺病和糖尿病慢性并发症。
- 糖尿病是胃轻瘫最常见病因,糖尿病患者出现上消化道症状时应考虑胃轻瘫可能。
局限性
- 基于行政理赔数据库,诊断准确性受编码影响。
- 明确胃轻瘫定义依赖胃排空闪烁显像检查,可能存在漏诊或选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although gastroparesis carries a considerable health care and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient demographics and disease etiology in a large US claims database. METHODS: This retrospective, cross-sectional analysis used de-identified, longitudinal patient-level enrollment and billing data for adults from the Optum Clinformatics Data Mart database, a large US national administrative health insurance claims database. Prevalence was age-, sex-, and geographical region-standardized using the 2018 US census. Descriptive analyses of demographic and clinical variables and underlying disease etiologies were performed. RESULTS: The overall standardized prevalence of gastroparesis was 267.7 (95% confidence interval [CI] 264.8-270.7) per 100,000 US adults, whereas prevalence of "definite" gastroparesis (individuals diagnosed within 3 months of gastric emptying scintigraphy testing with persistent symptoms for more than 3 months) was 21.5 (95% CI 20.6-22.4) per 100,000 persons. Patients with gastroparesis had an overall Charlson Comorbidity Index score of 4.2, indicating substantial comorbidity burden. The most frequently documented comorbidities were chronic pulmonary disease (46.4%), diabetes with chronic complication (37.3%), and peripheral vascular disease (30.4%). Patients most commonly had a diabetic etiology (57.4%; type 1, 5.7% and type 2, 51.7%), followed by postsurgical (15.0%), drug-induced (11.8%), and idiopathic (11.3%) etiologies. CONCLUSIONS: New evidence is provided regarding the prevalence, patient demographics, and etiology of gastroparesis in the US general population. Wider availability of reliable objective gastric emptying measures and further education of medical professionals in recognizing and diagnosing gastroparesis would benefit future studies and improve understanding of disease epidemiology.
引用
- Ye Y, Yin Y, Huh SY, et al. Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database. Gastroenterology. 2021. PMID: 34624355. doi:10.1053/j.gastro.2021.09.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。